Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …

G Zalcman, J Mazieres, J Margery, L Greillier… - The Lancet, 2016 - thelancet.com
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
被引用次数：938 相关文章

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …

G Zalcman, J Mazieres, J Margery… - Lancet (London …, 2015 - europepmc.org
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
[PDF] ifct.fr

[PDF][PDF] Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open …

G Zalcman, J Mazieres, J Margery, L Greillier… - 2015 - ifct.fr
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …

G Zalcman, J Mazieres, J Margery, L Greillier… - The Lancet, 2016 - infona.pl
Malignant pleural mesothelioma is an aggressive cancer with poor prognosis, linked to
occupational asbestos exposure. Vascular endothelial growth factor is a key mitogen for …
[PDF] clydesideactiononasbestos.org.uk

[PDF][PDF] Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open …

G Zalcman, J Mazieres, J Margery, L Greillier… - 2015 - clydesideactiononasbestos.org.uk
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …

G Zalcman, J Mazieres, J Margery… - Lancet (London …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …

G Zalcman, J Mazieres, J Margery, L Greillier… - The Lancet, 2016 - thelancet.com
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …

G Zalcman, J Mazieres, J Margery, L Greillier… - The Lancet, 2016 - Elsevier
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

[引用][C] Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open …

G Zalcman, J Mazieres, J Margery, L Greillier… - The Lancet, 2016 - cir.nii.ac.jp
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin
Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial | CiNii Research …
[PDF] clydesideactiononasbestos.org.uk

[PDF][PDF] Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open …

G Zalcman, J Mazieres, J Margery, L Greillier… - 2015 - clydesideactiononasbestos.org.uk
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …